VCBeat Health Contact Us
Home Takeda's $4 Billion TYK2 Inhibitor Zasocitinib Outperforms BMS’s Deucravacitinib in Phase 3 Head-to-Head Trial

Takeda's $4 Billion TYK2 Inhibitor Zasocitinib Outperforms BMS’s Deucravacitinib in Phase 3 Head-to-Head Trial

Jun 11, 2026 20:40 CST Updated Jun 12, 03:09